|
1
|
Zamaraev AV, Kopeina GS, Prokhorova EA,
Zhivotovsky B and Lavrik IN: Post-translational modification of
caspases: The other side of apoptosis regulation. Trends Cell Biol.
27:322–339. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu J, Qian C and Cao X:
Post-translational modification control of innate immunity.
Immunity. 45:15–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bode AM and Dong Z: Post-translational
modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Venne AS, Kollipara L and Zahedi RP: The
next level of complexity: Crosstalk of posttranslational
modifications. Proteomics. 14:513–524. 2014. View Article : Google Scholar
|
|
5
|
Woolfrey KM and Dell'Acqua ML:
Coordination of protein phosphorylation and dephosphorylation in
synaptic plasticity. J Biol Chem. 290:28604–28612. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olsen JV, Blagoev B, Gnad F, Macek B,
Kumar C, Mortensen P and Mann M: Global, in vivo, and site-specific
phosphorylation dynamics in signaling networks. Cell. 127:635–648.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson LN: The regulation of protein
phosphorylation. Biochem Soc Trans. 37:627–641. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang X and Chen ZJ: The role of
ubiquitylation in immune defence and pathogen evasion. Nat Rev
Immunol. 12:35–48. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vucic D, Dixit VM and Wertz IE:
Ubiquitylation in apoptosis: A post-translational modification at
the edge of life and death. Nat Rev Mol Cell Biol. 12:439–452.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fulda S, Rajalingam K and Dikic I:
Ubiquitylation in immune disorders and cancer: From molecular
mechanisms to therapeutic implications. EMBO Mol Med. 4:545–556.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Komander D and Rape M: The ubiquitin code.
Annu Rev Biochem. 81:203–229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choudhary C, Weinert BT, Nishida Y, Verdin
E and Mann M: The growing landscape of lysine acetylation links
metabolism and cell signalling. Nat Rev Mol Cell Biol. 15:536–550.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo M and Huang BX: Integration of
phosphoproteomic, chemical, and biological strategies for the
functional analysis of targeted protein phosphorylation.
Proteomics. 13:424–437. 2013. View Article : Google Scholar
|
|
14
|
Kim W, Bennett EJ, Huttlin EL, Guo A, Li
J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, et al: Systematic
and quantitative assessment of the ubiquitin-modified proteome. Mol
Cell. 44:325–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lamoliatte F, McManus FP, Maarifi G,
Chelbi-Alix MK and Thibault P: Uncovering the SUMOylation and
ubiquitylation crosstalk in human cells using sequential peptide
immunopurification. Nat Commun. 8:141092017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Biggar KK and Li SS: Non-histone protein
methylation as a regulator of cellular signalling and function. Nat
Rev Mol Cell Biol. 16:5–17. 2015. View Article : Google Scholar
|
|
17
|
Choudhary C, Kumar C, Gnad F, Nielsen ML,
Rehman M, Walther TC, Olsen JV and Mann M: Lysine acetylation
targets protein complexes and co-regulates major cellular
functions. Science. 325:834–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Drazic A, Myklebust LM, Ree R and Arnesen
T: The world of protein acetylation. Biochim Biophys Acta.
1864:1372–1401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Menzies KJ, Zhang H, Katsyuba E and Auwerx
J: Protein acetylation in metabolism - metabolites and cofactors.
Nat Rev Endocrinol. 12:43–60. 2016. View Article : Google Scholar
|
|
20
|
Verdin E and Ott M: 50 years of protein
acetylation: From gene regulation to epigenetics, metabolism and
beyond. Nat Rev Mol Cell Biol. 16:258–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bettermann K, Benesch M, Weis S and
Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett.
316:113–125. 2012. View Article : Google Scholar
|
|
22
|
Eifler K and Vertegaal AC:
SUMOylation-mediated regulation of cell cycle progression and
cancer. Trends Biochem Sci. 40:779–793. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Flotho A and Melchior F: Sumoylation: A
regulatory protein modification in health and disease. Annu Rev
Biochem. 82:357–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rabellino A, Andreani C and Scaglioni PP:
The role of PIAS SUMO E3-ligases in cancer. Cancer Res.
77:1542–1547. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seeler JS and Dejean A: SUMO and the
robustness of cancer. Nat Rev Cancer. 17:184–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y and Dasso M: SUMOylation and
deSUMOylation at a glance. J Cell Sci. 122:4249–4252. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mahajan R, Delphin C, Guan T, Gerace L and
Melchior F: A small ubiquitin-related polypeptide involved in
targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell.
88:97–107. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matunis MJ, Coutavas E and Blobel G: A
novel ubiquitin-like modification modulates the partitioning of the
Ran-GTPase-activating protein RanGAP1 between the cytosol and the
nuclear pore complex. J Cell Biol. 135:1457–1470. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saitoh H and Hinchey J: Functional
heterogeneity of small ubiquitin-related protein modifiers SUMO-1
versus SUMO-2/3. J Biol Chem. 275:6252–6258. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Owerbach D, McKay EM, Yeh ET, Gabbay KH
and Bohren KM: A proline-90 residue unique to SUMO-4 prevents
maturation and sumoylation. Biochem Biophys Res Commun.
337:517–520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang CY, Yang P, Li M and Gong F:
Characterization of a negative feedback network between SUMO4
expression and NFkappaB transcriptional activity. Biochem Biophys
Res Commun. 381:477–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miura K, Jin JB and Hasegawa PM:
Sumoylation, a post-translational regulatory process in plants.
Curr Opin Plant Biol. 10:495–502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tatham MH, Jaffray E, Vaughan OA, Desterro
JM, Botting CH, Naismith JH and Hay RT: Polymeric chains of SUMO-2
and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and
Ubc9. J Biol Chem. 276:35368–35374. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nayak A and Müller S: SUMO-specific
proteases/isopeptidases: SENPs and beyond. Genome Biol. 15:4222014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Desterro JM, Rodriguez MS, Kemp GD and Hay
RT: Identification of the enzyme required for activation of the
small ubiquitin-like protein SUMO-1. J Biol Chem. 274:10618–10624.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tatham MH, Kim S, Jaffray E, Song J, Chen
Y and Hay RT: Unique binding interactions among Ubc9, SUMO and
RanBP2 reveal a mechanism for SUMO paralog selection. Nat Struct
Mol Biol. 12:67–74. 2005. View Article : Google Scholar
|
|
37
|
Bernier-Villamor V, Sampson DA, Matunis MJ
and Lima CD: Structural basis for E2-mediated SUMO conjugation
revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and
RanGAP1. Cell. 108:345–356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Werner A, Flotho A and Melchior F: The
RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase.
Mol Cell. 46:287–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cappadocia L, Pichler A and Lima CD:
Structural basis for catalytic activation by the human ZNF451 SUMO
E3 ligase. Nat Struct Mol Biol. 22:968–975. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rytinki MM, Kaikkonen S, Pehkonen P,
Jääskeläinen T and Palvimo JJ: PIAS proteins: Pleiotropic
interactors associated with SUMO. Cell Mol Life Sci. 66:3029–3041.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stephan AK, Kliszczak M and Morrison CG:
The Nse2/Mms21 SUMO ligase of the Smc5/6 complex in the maintenance
of genome stability. FEBS Lett. 585:2907–2913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Reverter D and Lima CD: Insights into E3
ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex.
Nature. 435:687–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang SH and Sharrocks AD: The SUMO E3
ligase activity of Pc2 is coordinated through a SUMO interaction
motif. Mol Cell Biol. 30:2193–2205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kagey MH, Melhuish TA and Wotton D: The
polycomb protein Pc2 is a SUMO E3. Cell. 113:127–137. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hatakeyama S: TRIM family proteins: Roles
in autophagy, immunity, and carcinogenesis. Trends Biochem Sci.
42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Koliopoulos MG, Esposito D, Christodoulou
E, Taylor IA and Rittinger K: Functional role of TRIM E3 ligase
oligomerization and regulation of catalytic activity. EMBO J.
35:1204–1218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hickey CM, Wilson NR and Hochstrasser M:
Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol.
13:755–766. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mendes AV, Grou CP, Azevedo JE and Pinto
MP: Evaluation of the activity and substrate specificity of the
human SENP family of SUMO proteases. Biochim Biophys Acta.
1863:139–147. 2016. View Article : Google Scholar
|
|
49
|
Shin EJ, Shin HM, Nam E, Kim WS, Kim JH,
Oh BH and Yun Y: DeSUMOylating isopeptidase: A second class of SUMO
protease. EMBO Rep. 13:339–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yeh ET: SUMOylation and De-SUMOylation:
Wrestling with life's processes. J Biol Chem. 284:8223–8227. 2009.
View Article : Google Scholar :
|
|
51
|
Kim JH and Baek SH: Emerging roles of
desumoylating enzymes. Biochim Biophys Acta. 1792:155–162. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang CJ, Wu D, Khan FA and Huo LJ:
DeSUMOylation: An important therapeutic target and protein
regulatory event. DNA Cell Biol. 34:652–660. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Enchev RI, Schulman BA and Peter M:
Protein neddylation: Beyond cullin-RING ligases. Nat Rev Mol Cell
Biol. 16:30–44. 2015. View Article : Google Scholar
|
|
54
|
Bergink S and Jentsch S: Principles of
ubiquitin and SUMO modifications in DNA repair. Nature.
458:461–467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Thomson TM and Guerra-Rebollo M: Ubiquitin
and SUMO signalling in DNA repair. Biochem Soc Trans. 38:116–131.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ulrich HD: Ubiquitin and SUMO in DNA
repair at a glance. J Cell Sci. 125:249–254. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jackson SP and Durocher D: Regulation of
DNA damage responses by ubiquitin and SUMO. Mol Cell. 49:795–807.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sarangi P and Zhao X: SUMO-mediated
regulation of DNA damage repair and responses. Trends Biochem Sci.
40:233–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Seeler JS and Dejean A: Nuclear and
unclear functions of SUMO. Nat Rev Mol Cell Biol. 4:690–699. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Stielow B, Sapetschnig A, Krüger I, Kunert
N, Brehm A, Boutros M and Suske G: Identification of SUMO-dependent
chromatin-associated transcriptional repression components by a
genome-wide RNAi screen. Mol Cell. 29:742–754. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhong S, Müller S, Ronchetti S, Freemont
PS, Dejean A and Pandolfi PP: Role of SUMO-1-modified PML in
nuclear body formation. Blood. 95:2748–2752. 2000.PubMed/NCBI
|
|
62
|
Schimmel J, Eifler K, Sigurðsson JO,
Cuijpers SA, Hendriks IA, Verlaan-de Vries M, Kelstrup CD,
Francavilla C, Medema RH, Olsen JV, et al: Uncovering SUMOylation
dynamics during cell-cycle progression reveals FoxM1 as a key
mitotic SUMO target protein. Mol Cell. 53:1053–1066. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pichler A, Knipscheer P, Oberhofer E, van
Dijk WJ, Körner R, Olsen JV, Jentsch S, Melchior F and Sixma TK:
SUMO modification of the ubiquitin-conjugating enzyme E2-25K. Nat
Struct Mol Biol. 12:264–269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ouyang KJ, Woo LL, Zhu J, Huo D, Matunis
MJ and Ellis NA: SUMO modification regulates BLM and RAD51
interaction at damaged replication forks. PLoS Biol.
7:e10002522009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Keusekotten K, Bade VN, Meyer-Teschendorf
K, Sriramachandran AM, Fischer-Schrader K, Krause A, Horst C,
Schwarz G, Hofmann K, Dohmen RJ, et al: Multivalent interactions of
the SUMO-interaction motifs in RING finger protein 4 determine the
specificity for chains of the SUMO. Biochem J. 457:207–214. 2014.
View Article : Google Scholar :
|
|
66
|
Song J, Durrin LK, Wilkinson TA, Krontiris
TG and Chen Y: Identification of a SUMO-binding motif that
recognizes SUMO-modified proteins. Proc Natl Acad Sci USA.
101:14373–14378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Merrill JC, Melhuish TA, Kagey MH, Yang
SH, Sharrocks AD and Wotton D: A role for non-covalent SUMO
interaction motifs in Pc2/CBX4 E3 activity. PLoS One. 5:e87942010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rodríguez JA: Interplay between nuclear
transport and ubiquitin/SUMO modifications in the regulation of
cancer-related proteins. Semin Cancer Biol. 27:11–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Müller S, Ledl A and Schmidt D: SUMO: A
regulator of gene expression and genome integrity. Oncogene.
23:1998–2008. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Nie M and Boddy MN: Cooperativity of the
SUMO and ubiquitin pathways in genome stability. Biomolecules.
6:142016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Melchior F, Schergaut M and Pichler A:
SUMO: Ligases, isopeptidases and nuclear pores. Trends Biochem Sci.
28:612–618. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Eifler K and Vertegaal AC: Mapping the
SUMOylated landscape. FEBS J. 282:3669–3680. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Choi SG, Kim H, Jeong EI, Lee HJ, Park S,
Lee SY, Lee HJ, Lee SW, Chung CH and Jung YK: SUMO-Modified FADD
recruits cytosolic Drp1 and caspase-10 to mitochondria for
regulated necrosis. Mol Cell Biol. 37:372017. View Article : Google Scholar
|
|
74
|
Hendriks IA and Vertegaal AC: A
comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell
Biol. 17:581–595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Peuscher MH and Jacobs JJ:
Posttranslational control of telomere maintenance and the telomere
damage response. Cell Cycle. 11:1524–1534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
von Wangenheim KH and Peterson HP: The
role of cell differentiation in controlling cell multiplication and
cancer. J Cancer Res Clin Oncol. 134:725–741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Vlachostergios PJ and Papandreou CN: The
role of the small ubiquitin-related modifier (SUMO) pathway in
prostate cancer. Biomolecules. 2:240–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zheng Z, Cai C, Omwancha J, Chen SY,
Baslan T and Shemshedini L: SUMO-3 enhances androgen receptor
transcriptional activity through a sumoylation-independent
mechanism in prostate cancer cells. J Biol Chem. 281:4002–4012.
2006. View Article : Google Scholar
|
|
79
|
Bawa-Khalfe T, Cheng J, Wang Z and Yeh ET:
Induction of the SUMO-specific protease 1 transcription by the
androgen receptor in prostate cancer cells. J Biol Chem.
282:37341–37349. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hu L, Yang F, Lu L and Dai W:
Arsenic-induced sumoylation of Mus81 is involved in regulating
genomic stability. Cell Cycle. 16:802–811. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bawa-Khalfe T, Yang FM, Ritho J, Lin HK,
Cheng J and Yeh ET: SENP1 regulates PTEN stability to dictate
prostate cancer development. Oncotarget. 8:17651–17664. 2017.
View Article : Google Scholar :
|
|
82
|
Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM
and Yeh ET: SENP1 induces prostatic intraepithelial neoplasia
through multiple mechanisms. J Biol Chem. 285:25859–25866. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li S, Wang M, Qu X, Xu Z, Yang Y, Su Q and
Wu H: SUMOylation of PES1 upregulates its stability and function
via inhibiting its ubiquitination. Oncotarget. 7:50522–50534.
2016.PubMed/NCBI
|
|
84
|
Finkbeiner E, Haindl M, Raman N and Muller
S: SUMO routes ribosome maturation. Nucleus. 2:527–532. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lecona E, Rodriguez-Acebes S, Specks J,
Lopez-Contreras AJ, Ruppen I, Murga M, Muñoz J, Mendez J and
Fernandez-Capetillo O: USP7 is a SUMO deubiquitinase essential for
DNA replication. Nat Struct Mol Biol. 23:270–277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Smits VA and Freire R: USP7/HAUSP: A SUMO
deubiquitinase at the heart of DNA replication. BioEssays.
38:863–868. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Sun L, Li H, Chen J, Iwasaki Y, Kubota T,
Matsuoka M, Shen A, Chen Q and Xu Y: PIASy mediates hypoxia-induced
SIRT1 transcriptional repression and epithelial-to-mesenchymal
transition in ovarian cancer cells. J Cell Sci. 126:3939–3947.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li S, Yang C, Hong Y, Bi H, Zhao F, Liu Y,
Ao X, Pang P, Xing X, Chang AK, et al: The transcriptional activity
of co-activator AIB1 is regulated by the SUMO E3 ligase PIAS1. Biol
Cell. 104:287–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
90
|
Kubota Y, O'Grady P, Saito H and Takekawa
M: Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK
pathway and cell transformation. Nat Cell Biol. 13:282–291. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Taylor EM, Copsey AC, Hudson JJ, Vidot S
and Lehmann AR: Identification of the proteins, including MAGEG1,
that make up the human SMC5-6 protein complex. Mol Cell Biol.
28:1197–1206. 2008. View Article : Google Scholar :
|
|
92
|
Wu J, Liu T, Rios Z, Mei Q, Lin X and Cao
S: Heat shock proteins and cancer. Trends Pharmacol Sci.
38:226–256. 2017. View Article : Google Scholar
|
|
93
|
Rachidi S, Sun S, Wu BX, Jones E, Drake
RR, Ogretmen B, Cowart LA, Clarke CJ, Hannun YA, Chiosis G, et al:
Endoplasmic reticulum heat shock protein gp96 maintains liver
homeostasis and promotes hepatocellular carcinogenesis. J Hepatol.
62:879–888. 2015. View Article : Google Scholar :
|
|
94
|
Pinto MP, Carvalho AF, Grou CP,
Rodríguez-Borges JE, Sá-Miranda C and Azevedo JE: Heat shock
induces a massive but differential inactivation of SUMO-specific
proteases. Biochim Biophys Acta. 1823:1958–1966. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Niskanen EA, Malinen M, Sutinen P,
Toropainen S, Paakinaho V, Vihervaara A, Joutsen J, Kaikkonen MU,
Sistonen L and Palvimo JJ: Global SUMOylation on active chromatin
is an acute heat stress response restricting transcription. Genome
Biol. 16:1532015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ishihara K, Fatma N, Bhargavan B,
Chhunchha B, Kubo E, Dey S, Takamura Y, Kumar A and Singh DP: Lens
epithelium-derived growth factor deSumoylation by Sumo-specific
protease-1 regulates its transcriptional activation of small heat
shock protein and the cellular response. FEBS J. 279:3048–3070.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Castorálová M, Březinová D, Svéda M, Lipov
J, Ruml T and Knejzlík Z: SUMO-2/3 conjugates accumulating under
heat shock or MG132 treatment result largely from new protein
synthesis. Biochim Biophys Acta. 1823:911–919. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Brunet Simioni M, De Thonel A, Hammann A,
Joly AL, Bossis G, Fourmaux E, Bouchot A, Landry J, Piechaczyk M
and Garrido C: Heat shock protein 27 is involved in SUMO-2/3
modification of heat shock factor 1 and thereby modulates the
transcription factor activity. Oncogene. 28:3332–3344. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Golebiowski F, Matic I, Tatham MH, Cole C,
Yin Y, Nakamura A, Cox J, Barton GJ, Mann M and Hay RT: System-wide
changes to SUMO modifications in response to heat shock. Sci
Signal. 2:ra242009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Liu HW, Zhang J, Heine GF, Arora M, Gulcin
Ozer H, Onti-Srinivasan R, Huang K and Parvin JD: Chromatin
modification by SUMO-1 stimulates the promoters of translation
machinery genes. Nucleic Acids Res. 40:10172–10186. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Aguilar-Martinez E, Chen X, Webber A,
Mould AP, Seifert A, Hay RT and Sharrocks AD: Screen for
multi-SUMO-binding proteins reveals a multi-SIM-binding mechanism
for recruitment of the transcriptional regulator ZMYM2 to
chromatin. Proc Natl Acad Sci USA. 112:E4854–E4863. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Amente S, Lavadera ML, Palo GD and Majello
B: SUMO-activating SAE1 transcription is positively regulated by
Myc. Am J Cancer Res. 2:330–334. 2012.PubMed/NCBI
|
|
103
|
Kessler JD, Kahle KT, Sun T, Meerbrey KL,
Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et
al: A SUMOylation-dependent transcriptional subprogram is required
for Myc-driven tumorigenesis. Science. 335:348–353. 2012.
View Article : Google Scholar
|
|
104
|
Hoellein A, Fallahi M, Schoeffmann S,
Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A,
Peschel C, et al: Myc-induced SUMOylation is a therapeutic
vulnerability for B-cell lymphoma. Blood. 124:2081–2090. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
González-Prieto R, Cuijpers SA, Kumar R,
Hendriks IA and Vertegaal AC: c-Myc is targeted to the proteasome
for degradation in a SUMOylation-dependent manner, regulated by
PIAS1, SENP7 and RNF4. Cell Cycle. 14:1859–1872. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Mo YY, Yu Y, Theodosiou E, Ee PL and Beck
WT: A role for Ubc9 in tumorigenesis. Oncogene. 24:2677–2683. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mattoscio D, Casadio C, Miccolo C, Maffini
F, Raimondi A, Tacchetti C, Gheit T, Tagliabue M, Galimberti VE, De
Lorenzi F, et al: Autophagy regulates UBC9 levels during
viral-mediated tumorigenesis. PLoS Pathog. 13:e10062622017.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Lin CH, Liu SY and Lee EH: SUMO
modification of Akt regulates global SUMOylation and substrate
SUMOylation specificity through Akt phosphorylation of Ubc9 and
SUMO1. Oncogene. 35:595–607. 2016. View Article : Google Scholar
|
|
109
|
Li R, Wei J, Jiang C, Liu D, Deng L, Zhang
K and Wang P: Akt SUMOylation regulates cell proliferation and
tumorigenesis. Cancer Res. 73:5742–5753. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Moschos SJ, Jukic DM, Athanassiou C,
Bhargava R, Dacic S, Wang X, Kuan SF, Fayewicz SL, Galambos C,
Acquafondata M, et al: Expression analysis of Ubc9, the single
small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in
normal and malignant tissues. Hum Pathol. 41:1286–1298. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wu F, Zhu S, Ding Y, Beck WT and Mo YY:
MicroRNA-mediated regulation of Ubc9 expression in cancer cells.
Clin Cancer Res. 15:1550–1557. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Gylfe AE, Kondelin J, Turunen M,
Ristolainen H, Katainen R, Pitkänen E, Kaasinen E, Rantanen V,
Tanskanen T, Varjosalo M, et al: Identification of candidate
oncogenes in human colorectal cancers with microsatellite
instability. Gastroenterology. 145:540–3.e22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Packham S, Warsito D, Lin Y, Sadi S,
Karlsson R, Sehat B and Larsson O: Nuclear translocation of IGF-1R
via p150 (Glued) and an importin-β/RanBP2-dependent pathway in
cancer cells. Oncogene. 34:2227–2238. 2015. View Article : Google Scholar
|
|
114
|
Ritterhoff T, Das H, Hofhaus G, Schröder
RR, Flotho A and Melchior F: The RanBP2/RanGAP1*SUMO1/Ubc9 SUMO E3
ligase is a disassembly machine for Crm1-dependent nuclear export
complexes. Nat Commun. 7:114822016. View Article : Google Scholar
|
|
115
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Watanabe M and Hatakeyama S: TRIM proteins
and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI
|
|
117
|
Sho T, Tsukiyama T, Sato T, Kondo T, Cheng
J, Saku T, Asaka M and Hatakeyama S: TRIM29 negatively regulates
p53 via inhibition of Tip60. Biochim Biophys Acta. 1813:1245–1253.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Noguchi K, Okumura F, Takahashi N, Kataoka
A, Kamiyama T, Todo S and Hatakeyama S: TRIM40 promotes neddylation
of IKKγ and is downregulated in gastrointestinal cancers.
Carcinogenesis. 32:995–1004. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Shibata M, Sato T, Nukiwa R, Ariga T and
Hatakeyama S: TRIM45 negatively regulates NF-κB-mediated
transcription and suppresses cell proliferation. Biochem Biophys
Res Commun. 423:104–109. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wang J, Zhu J, Dong M, Yu H, Dai X and Li
K: Knockdown of tripartite motif containing 24 by lentivirus
suppresses cell growth and induces apoptosis in human colorectal
cancer cells. Oncol Res. 22:39–45. 2014. View Article : Google Scholar
|
|
121
|
Chen Y, Guo Y, Yang H, Shi G, Xu G, Shi J,
Yin N and Chen D: TRIM66 overexpresssion contributes to
osteosarcoma carcinogenesis and indicates poor survival outcome.
Oncotarget. 6:23708–23719. 2015.PubMed/NCBI
|
|
122
|
Chen W, Zhao K, Miao C, Xu A, Zhang J, Zhu
J, Su S and Wang Z: Silencing Trim59 inhibits invasion/migration
and epithelial-to-mesenchymal transition via TGF-β/Smad2/3
signaling pathway in bladder cancer cells. Onco Targets Ther.
10:1503–1512. 2017. View Article : Google Scholar :
|
|
123
|
Bawa-Khalfe T and Yeh ET: SUMO losing
balance: SUMO proteases disrupt SUMO homeostasis to facilitate
cancer development and progression. Genes Cancer. 1:748–752. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Kunz K, Wagner K, Mendler L, Hölper S,
Dehne N and Müller S: SUMO signaling by hypoxic inactivation of
SUMO-specific isopeptidases. Cell Reports. 16:3075–3086. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Chen CH, Chang CC, Lee TH, Luo M, Huang P,
Liao PH, Wei S, Li FA, Chen RH, Zhou XZ, et al: SENP1 deSUMOylates
and regulates Pin1 protein activity and cellular function. Cancer
Res. 73:3951–3962. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Shen HJ, Zhu HY, Yang C and Ji F: SENP2
regulates hepatocellular carcinoma cell growth by modulating the
stability of β-catenin. Asian Pac J Cancer Prev. 13:3583–3587.
2012. View Article : Google Scholar
|
|
127
|
Cheng J, Su M, Jin Y, Xi Q, Deng Y, Chen
J, Wang W, Chen Y, Chen L, Shi N, et al: Upregulation of
SENP3/SMT3IP1 promotes epithelial ovarian cancer progression and
forecasts poor prognosis. Tumour Biol. 39:10104283176945432017.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ding X, Sun J, Wang L, Li G, Shen Y, Zhou
X and Chen W: Overexpression of SENP5 in oral squamous cell
carcinoma and its association with differentiation. Oncol Rep.
20:1041–1045. 2008.PubMed/NCBI
|
|
129
|
Wang K and Zhang XC: Inhibition of SENP5
suppresses cell growth and promotes apoptosis in osteosarcoma
cells. Exp Ther Med. 7:1691–1695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Jin ZL, Pei H, Xu YH, Yu J and Deng T: The
SUMO-specific protease SENP5 controls DNA damage response and
promotes tumorigenesis in hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 20:3566–3573. 2016.PubMed/NCBI
|
|
131
|
Bawa-Khalfe T, Lu LS, Zuo Y, Huang C, Dere
R, Lin FM and Yeh ET: Differential expression of SUMO-specific
protease 7 variants regulates epithelial-mesenchymal transition.
Proc Natl Acad Sci USA. 109:17466–17471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Stelter P and Ulrich HD: Control of
spontaneous and damage-induced mutagenesis by SUMO and ubiquitin
conjugation. Nature. 425:188–191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Gali H, Juhasz S, Morocz M, Hajdu I,
Fatyol K, Szukacsov V, Burkovics P and Haracska L: Role of SUMO
modification of human PCNA at stalled replication fork. Nucleic
Acids Res. 40:6049–6059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Armstrong AA, Mohideen F and Lima CD:
Recognition of SUMO-modified PCNA requires tandem receptor motifs
in Srs2. Nature. 483:59–63. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Morris JR, Boutell C, Keppler M, Densham
R, Weekes D, Alamshah A, Butler L, Galanty Y, Pangon L, Kiuchi T,
et al: The SUMO modification pathway is involved in the BRCA1
response to genotoxic stress. Nature. 462:886–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Guzzo CM, Berndsen CE, Zhu J, Gupta V,
Datta A, Greenberg RA, Wolberger C and Matunis MJ: RNF4-dependent
hybrid SUMO-ubiquitin chains are signals for RAP80 and thereby
mediate the recruitment of BRCA1 to sites of DNA damage. Sci
Signal. 5:ra882012. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Galanty Y, Belotserkovskaya R, Coates J,
Polo S, Miller KM and Jackson SP: Mammalian SUMO E3-ligases PIAS1
and PIAS4 promote responses to DNA double-strand breaks. Nature.
462:935–939. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Pfeiffer A, Luijsterburg MS, Acs K,
Wiegant WW, Helfricht A, Herzog LK, Minoia M, Böttcher C, Salomons
FA, van Attikum H, et al: Ataxin-3 consolidates the MDC1-dependent
DNA double-strand break response by counteracting the SUMO-targeted
ubiquitin ligase RNF4. EMBO J. 36:1066–1083. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Yin Y, Seifert A, Chua JS, Maure JF,
Golebiowski F and Hay RT: SUMO-targeted ubiquitin E3 ligase RNF4 is
required for the response of human cells to DNA damage. Genes Dev.
26:1196–1208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Galanty Y, Belotserkovskaya R, Coates J
and Jackson SP: RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes
DNA double-strand break repair. Genes Dev. 26:1179–1195. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
He X, Riceberg J, Pulukuri SM, Grossman S,
Shinde V, Shah P, Brownell JE, Dick L, Newcomb J and Bence N:
Characterization of the loss of SUMO pathway function on cancer
cells and tumor proliferation. PLoS One. 10:e01238822015.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Zhang J, Huang FF, Wu DS, Li WJ, Zhan HE,
Peng MY, Fang P, Cao PF, Zhang MM, Zeng H, et al: SUMOylation of
insulin-like growth factor 1 receptor, promotes proliferation in
acute myeloid leukemia. Cancer Lett. 357:297–306. 2015. View Article : Google Scholar
|
|
143
|
You L, Liu C, Tang H, Liao Y and Fu S:
Advances in targeting insulin-like growth factor signaling pathway
in cancer treatment. Curr Pharm Des. 20:2899–2911. 2014. View Article : Google Scholar
|
|
144
|
Oh Y and Chung KC: Small ubiquitin-like
modifier (SUMO) modification of zinc finger protein 131 potentiates
its negative effect on estrogen signaling. J Biol Chem.
287:17517–17529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Schulz S, Chachami G, Kozaczkiewicz L,
Winter U, Stankovic-Valentin N, Haas P, Hofmann K, Urlaub H, Ovaa
H, Wittbrodt J, et al: Ubiquitin-specific protease-like 1 (USPL1)
is a SUMO isopeptidase with essential, non-catalytic functions.
EMBO Rep. 13:930–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Xu J, Sun HY, Xiao FJ, Wang H, Yang Y,
Wang L, Gao CJ, Guo ZK, Wu CT and Wang LS: SENP1 inhibition induces
apoptosis and growth arrest of multiple myeloma cells through
modulation of NF-κB signaling. Biochem Biophys Res Commun.
460:409–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Huang HJ, Zhou LL, Fu WJ, Zhang CY, Jiang
H, Du J and Hou J: β-catenin SUMOylation is involved in the
dysregulated proliferation of myeloma cells. Am J Cancer Res.
5:309–320. 2014.
|
|
148
|
Toropainen S, Malinen M, Kaikkonen S,
Rytinki M, Jääskeläinen T, Sahu B, Jänne OA and Palvimo JJ: SUMO
ligase PIAS1 functions as a target gene selective androgen receptor
coregulator on prostate cancer cell chromatin. Nucleic Acids Res.
43:848–861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wang W, Chen Y, Wang S, Hu N, Cao Z, Wang
W, Tong T and Zhang X: PIASxα ligase enhances SUMO1 modification of
PTEN protein as a SUMO E3 ligase. J Biol Chem. 289:3217–3230. 2014.
View Article : Google Scholar
|
|
150
|
Wen D, Xu Z, Xia L, Liu X, Tu Y, Lei H,
Wang W, Wang T, Song L, Ma C, et al: Important role of SUMOylation
of Spliceosome factors in prostate cancer cells. J Proteome Res.
13:3571–3582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Huang W, He T, Chai C, Yang Y, Zheng Y,
Zhou P, Qiao X, Zhang B, Liu Z, Wang J, et al: Triptolide inhibits
the proliferation of prostate cancer cells and down-regulates
SUMO-specific protease 1 expression. PLoS One. 7:e376932012.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Shao DF, Wang XH, Li ZY, Xing XF, Cheng
XJ, Guo T, Du H, Hu Y, Dong B, Ding N, et al: High-level SAE2
promotes malignant phenotype and predicts outcome in gastric
cancer. Am J Cancer Res. 5:140–154. 2014.
|
|
153
|
Paakinaho V, Kaikkonen S, Makkonen H,
Benes V and Palvimo JJ: SUMOylation regulates the chromatin
occupancy and anti-proliferative gene programs of glucocorticoid
receptor. Nucleic Acids Res. 42:1575–1592. 2014. View Article : Google Scholar :
|
|
154
|
Hua G, Ganti KP and Chambon P:
Glucocorticoid-induced tethered transrepression requires
SUMOylation of GR and formation of a SUMO-SMRT/NCoR1-HDAC3
repressing complex. Proc Natl Acad Sci USA. 113:E635–E643. 2016.
View Article : Google Scholar :
|
|
155
|
Bies J, Sramko M and Wolff L:
Stress-induced phosphorylation of Thr486 in c-Myb by p38
mitogenactivated protein kinases attenuates conjugation of
SUMO-2/3. J Biol Chem. 288:36983–36993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Du JX, McConnell BB and Yang VW: A small
ubiquitin-related modifier-interacting motif functions as the
transcriptional activation domain of Krüppel-like factor 4. J Biol
Chem. 285:28298–28308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Han Y, Huang C, Sun X, Xiang B, Wang M,
Yeh ET, Chen Y, Li H, Shi G, Cang H, et al: SENP3-mediated
de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated
with accelerated cell proliferation under mild oxidative stress. J
Biol Chem. 285:12906–12915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Carter S, Bischof O, Dejean A and Vousden
KH: C-terminal modifications regulate MDM2 dissociation and nuclear
export of p53. Nat Cell Biol. 9:428–435. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Dadke S, Cotteret S, Yip SC, Jaffer ZM,
Haj F, Ivanov A, Rauscher F III, Shuai K, Ng T, Neel BG, et al:
Regulation of protein tyrosine phosphatase 1B by sumoylation. Nat
Cell Biol. 9:80–85. 2007. View Article : Google Scholar
|
|
160
|
Jin L, Shen K, Chen T, Zhang H and Yu W:
SUMO-1 gene silencing inhibits proliferation and promotes apoptosis
of human gastric cancer SGC-7901 Cells. Cell Physiol Biochem.
41:987–998. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Wang B, Tang J, Liao D, Wang G, Zhang M,
Sang Y, Cao J, Wu Y, Zhang R, Li S, et al: Chromobox homolog 4 is
correlated with prognosis and tumor cell growth in hepatocellular
carcinoma. Ann Surg Oncol. 20(Suppl 3): S684–S692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Bellail AC, Olson JJ and Hao C: SUMO1
modification stabilizes CDK6 protein and drives the cell cycle and
glioblastoma progression. Nat Commun. 5:42342014. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wang Z, Jin J, Zhang J, Wang L and Cao J:
Depletion of SENP1 suppresses the proliferation and invasion of
triple-negative breast cancer cells. Oncol Rep. 36:2071–2078. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Wang Q, Xia N, Li T, Xu Y, Zou Y, Zuo Y,
Fan Q, Bawa-Khalfe T, Yeh ET and Cheng J: SUMO-specific protease-1
promotes prostate cancer progression and metastasis. Oncogene.
32:2493–2498. 2013. View Article : Google Scholar
|
|
165
|
Tan M, Gong H, Wang J, Tao L, Xu D, Bao E,
Liu Z and Qiu J: SENP2 regulates MMP13 expression in a bladder
cancer cell line through SUMOylation of TBL1/TBLR1. Sci Rep.
5:139962015. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Wang X, Li L, Wu Y, Zhang R, Zhang M, Liao
D, Wang G, Qin G, Xu RH and Kang T: CBX4 suppresses metastasis via
recruitment of HDAC3 to the Runx2 promoter in colorectal carcinoma.
Cancer Res. 76:7277–7289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Li J, Xu Y, Long XD, Wang W, Jiao HK, Mei
Z, Yin QQ, Ma LN, Zhou AW, Wang LS, et al: Cbx4 governs HIF-1α to
potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3
ligase activity. Cancer Cell. 25:118–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Mei Z, Jiao H, Wang W, Li J, Chen G and Xu
Y: Polycomb chromobox 4 enhances migration and pulmonary metastasis
of hepatocellular carcinoma cell line MHCC97L. Sci China Life Sci.
57:610–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Liu S, Long J, Yuan B, Zheng M, Xiao M, Xu
J, Lin X and Feng XH: SUMO modification reverses inhibitory effects
of Smad nuclear interacting protein-1 in TGF-β responses. J Biol
Chem. 291:24418–24430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Zhang W, Sun H, Shi X, Wang H, Cui C, Xiao
F, Wu C, Guo X and Wang L: SENP1 regulates hepatocyte growth
factor-induced migration and epithelial-mesenchymal transition of
hepatocellular carcinoma. Tumour Biol. 37:7741–7748. 2016.
View Article : Google Scholar
|
|
171
|
Hu W, Fan C, Jiang P, Ma Z, Yan X, Di S,
Jiang S, Li T, Cheng Y and Yang Y: Emerging role of N-myc
downstream-regulated gene 2 (NDRG2) in cancer. Oncotarget.
7:209–223. 2016.
|
|
172
|
Tantai J, Pan X and Hu D: RNF4-mediated
SUMOylation is essential for NDRG2 suppression of lung
adenocarcinoma. Oncotarget. 7:26837–26843. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Ryu T, Spatola B, Delabaere L, Bowlin K,
Hopp H, Kunitake R, Karpen GH and Chiolo I: Heterochromatic breaks
move to the nuclear periphery to continue recombinational repair.
Nat Cell Biol. 17:1401–1411. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Liu X, Xu Y, Pang Z, Guo F, Qin Q, Yin T,
Sang Y, Feng C, Li X, Jiang L, et al: Knockdown of SUMO-activating
enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances
chemotherapy sensitivity in small cell lung cancer. J Hematol
Oncol. 8:672015. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Ma C, Wu B, Huang X, Yuan Z, Nong K, Dong
B, Bai Y, Zhu H, Wang W and Ai K: SUMO-specific protease 1
regulates pancreatic cancer cell proliferation and invasion by
targeting MMP-9. Tumour Biol. 35:12729–12735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Cashman R, Cohen H, Ben-Hamo R, Zilberberg
A and Efroni S: SENP5 mediates breast cancer invasion via a TGFβRI
SUMOylation cascade. Oncotarget. 5:1071–1082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Mooney SM, Grande JP, Salisbury JL and
Janknecht R: Sumoylation of p68 and p72 RNA helicases affects
protein stability and transactivation potential. Biochemistry.
49:1–10. 2010. View Article : Google Scholar
|
|
178
|
Tan MY, Mu XY, Liu B, Wang Y, Bao ED, Qiu
JX and Fan Y: SUMO-specific protease 2 suppresses cell migration
and invasion through inhibiting the expression of MMP13 in bladder
cancer cells. Cell Physiol Biochem. 32:542–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Garcia-Mata R, Boulter E and Burridge K:
The 'invisible hand': Regulation of RHO GTPases by RHOGDIs. Nat Rev
Mol Cell Biol. 12:493–504. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Yu J, Zhang D, Liu J, Li J, Yu Y, Wu XR
and Huang C: RhoGDI SUMOylation at Lys-138 increases its binding
activity to Rho GTPase and its inhibiting cancer cell motility. J
Biol Chem. 287:13752–13760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Castillo-Lluva S, Tatham MH, Jones RC,
Jaffray EG, Edmondson RD, Hay RT and Malliri A: SUMOylation of the
GTPase Rac1 is required for optimal cell migration. Nat Cell Biol.
12:1078–1085. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Núñez-O'Mara A, Gerpe-Pita A, Pozo S,
Carlevaris O, Urzelai B, Lopitz-Otsoa F, Rodríguez MS and Berra E:
PHD3-SUMO conjugation represses HIF1 transcriptional activity
independently of PHD3 catalytic activity. J Cell Sci. 128:40–49.
2015. View Article : Google Scholar
|
|
183
|
Zhao XY, Chen TT, Xia L, Guo M, Xu Y, Yue
F, Jiang Y, Chen GQ and Zhao KW: Hypoxia inducible factor-1
mediates expression of galectin-1: The potential role in
migration/invasion of colorectal cancer cells. Carcinogenesis.
31:1367–1375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Zhu S, Sachdeva M, Wu F, Lu Z and Mo YY:
Ubc9 promotes breast cell invasion and metastasis in a
sumoylation-independent manner. Oncogene. 29:1763–1772. 2010.
View Article : Google Scholar :
|
|
185
|
Li H, Niu H, Peng Y, Wang J and He P: Ubc9
promotes invasion and metastasis of lung cancer cells. Oncol Rep.
29:1588–1594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Luo J, Emanuele MJ, Li D, Creighton CJ,
Schlabach MR, Westbrook TF, Wong KK and Elledge SJ: A genome-wide
RNAi screen identifies multiple synthetic lethal interactions with
the Ras oncogene. Cell. 137:835–848. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Moschos SJ, Smith AP, Mandic M,
Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM
and Becker D: SAGE and antibody array analysis of
melanoma-infiltrated lymph nodes: Identification of Ubc9 as an
important molecule in advanced-stage melanomas. Oncogene.
26:4216–4225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Zhao Z, Tan X, Zhao A, Zhu L, Yin B, Yuan
J, Qiang B and Peng X: microRNA-214-mediated UBC9 expression in
glioma. BMB Rep. 45:641–646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Lu Z, Wu H and Mo YY: Regulation of bcl-2
expression by Ubc9. Exp Cell Res. 312:1865–1875. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Morrison CD, Parvani JG and Schiemann WP:
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer
Lett. 341:30–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Gilkes DM, Semenza GL and Wirtz D: Hypoxia
and the extracellular matrix: Drivers of tumour metastasis. Nat Rev
Cancer. 14:430–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Núñez-O'Mara A and Berra E: Deciphering
the emerging role of SUMO conjugation in the hypoxia-signaling
cascade. Biol Chem. 394:459–469. 2013.PubMed/NCBI
|
|
195
|
Shao R, Zhang FP, Tian F, Anders Friberg
P, Wang X, Sjöland H and Billig H: Increase of SUMO-1 expression in
response to hypoxia: Direct interaction with HIF-1alpha in adult
mouse brain and heart in vivo. FEBS Lett. 569:293–300. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Agbor TA, Cheong A, Comerford KM, Scholz
CC, Bruning U, Clarke A, Cummins EP, Cagney G and Taylor CT: Small
ubiquitin-related modifier (SUMO)-1 promotes glycolysis in hypoxia.
J Biol Chem. 286:4718–4726. 2011. View Article : Google Scholar :
|
|
197
|
Antico Arciuch VG, Tedesco L, Fuertes M
and Arzt E: Role of RSUME in inflammation and cancer. FEBS Lett.
589:3330–3335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Carbia-Nagashima A, Gerez J, Perez-Castro
C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F and Arzt E:
RSUME, a small RWD-containing protein, enhances SUMO conjugation
and stabilizes HIF-1alpha during hypoxia. Cell. 131:309–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Xu Y, Zuo Y, Zhang H, Kang X, Yue F, Yi Z,
Liu M, Yeh ET, Chen G and Cheng J: Induction of SENP1 in
endothelial cells contributes to hypoxia-driven VEGF expression and
angio-genesis. J Biol Chem. 285:36682–36688. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Childs BG, Baker DJ, Kirkland JL, Campisi
J and van Deursen JM: Senescence and apoptosis: Dueling or
complementary cell fates. EMBO Rep. 15:1139–1153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Davalos AR, Coppe JP, Campisi J and
Desprez PY: Senescent cells as a source of inflammatory factors for
tumor progression. Cancer Metastasis Rev. 29:273–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Lujambio A, Akkari L, Simon J, Grace D,
Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA,
Krizhanovsky V, et al: Non-cell-autonomous tumor suppression by
p53. Cell. 153:449–460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Ivanschitz L, Takahashi Y, Jollivet F,
Ayrault O, Le Bras M and de Thé H: PML IV/ARF interaction enhances
p53 SUMO-1 conjugation, activation, and senescence. Proc Natl Acad
Sci USA. 112:14278–14283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Neyret-Kahn H, Benhamed M, Ye T, Le Gras
S, Cossec JC, Lapaquette P, Bischof O, Ouspenskaia M, Dasso M,
Seeler J, et al: Sumoylation at chromatin governs coordinated
repression of a transcriptional program essential for cell growth
and proliferation. Genome Res. 23:1563–1579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Jiang Z, Fan Q, Zhang Z, Zou Y, Cai R,
Wang Q, Zuo Y and Cheng J: SENP1 deficiency promotes ER
stress-induced apoptosis by increasing XBP1 SUMOylation. Cell
Cycle. 11:1118–1122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Xia W, Tian H, Cai X, Kong H, Fu W, Xing
W, Wang Y, Zou M, Hu Y and Xu D: Inhibition of SUMO-specific
protease 1 induces apoptosis of astroglioma cells by regulating
NF-κB/Akt pathways. Gene. 595:175–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Sudharsan R and Azuma Y: The SUMO ligase
PIAS1 regulates UV-induced apoptosis by recruiting Daxx to
SUMOylated foci. J Cell Sci. 125:5819–5829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Zhou Y, Ji C, Cao M, Guo M, Huang W, Ni W,
Meng L, Yang H and Wei JF: Inhibitors targeting the SUMOylation
pathway: A patent review 2012–2015 (Review). Int J Mol Med.
41:3–12. 2018.
|
|
209
|
Scott DE, Bayly AR, Abell C and Skidmore
J: Small molecules, big targets: Drug discovery faces the
protein-protein interaction challenge. Nat Rev Drug Discov.
15:533–550. 2016. View Article : Google Scholar : PubMed/NCBI
|
